MBP and chronic myelogenous leukemia, BCR-ABL1 positive: Recent studies have described positive outcomes with a three-drug, timed-sequenced regimen (TSR) consisting of a purine analog followed by high-dose cytarabine and an anthracycline in the upfront setting for AML and could potentially improve outcomes for CML-MBP patients [4–6].